Tauns Laboratories (TYO:197A) has been granted a patent in Japan for a novel method and reagent to detect target substances, such as antigens, using immunoassay technology, according to a Tuesday filing on the Tokyo Stock Exchange.
This enables sensitive and cost-effective detection, advancing laboratory-grade testing through Point of Care Testing. It is expected to enhance clinic testing capabilities and contribute to more efficient medical care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.